COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
Temas Resources Announces Non-Brokered Private Placement of up to $1.5 Million
Temas Resources Corp. announces non-brokered private placement of up to 6,000,000 units at a price of $0.25 per share for gross proceeds of $1.5 million. The Company intends to use proceeds for advancing the La Blache project, marketing, and working capital -
COMMUNIQUÉ DE PRESSE
Vulcan Minerals Inc. - Red Cross Lake Delivers Stellar Nickel-Copper-Cobalt Soil Anomaly in Newfoundland
Vulcan Minerals Inc. announces impressive soil geochemical results from the Red Cross Lake Nickel-Copper-Cobalt Project in central Newfoundland, confirming significant potential for magmatic style mineralization in a favourable geologic environment, initiating permitting for advanced exploration including drilling in 2024 -
COMMUNIQUÉ DE PRESSE
Specificity Strengthens Client Services with the Appointment of Account Management Expert Shelby DeCarlo
Specificity Inc. (OTCQB:SPTY) announces Shelby DeCarlo as Client Success Manager, enhancing client support and retention. CEO Jason Wood expresses confidence in Shelby's ability to drive client success and contribute to the company's growth -
COMMUNIQUÉ DE PRESSE
Sparta Capital Announces Issuing of Management Cease Trade Order
Sparta Group (TSXV:SAY) provides an update on the Management Cease Trade Order received from the Alberta Securities Commission due to the delay in filing its annual financial statements. The Company expects to file the Annual Filings by March 29, 2024, while regular trading continues unaffected. The new management team assures business as usual during this period -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: VERBUND AG: Earnings forecast for financial year 2024 is significantly below market expectations
VERBUND AG announces significant deviation from market expectations in 2024 earnings forecast due to drop in wholesale prices for electricity and lower earnings contribution in the Grid segment -
COMMUNIQUÉ DE PRESSE
Belhaven Biopharma Announces Groundbreaking Clinical Results for Nasdepi, the Revolutionary Nasal Dry Powder Epinephrine Product
Belhaven Biopharma shares positive results from Phase 1 clinical trial of Nasdepi, a nasal dry powder epinephrine device for treating anaphylaxis. Successful investor round and Series A financing on the horizon
